Chiara Varamo - Concepedia

Author

Chiara Varamo

Candiolo Cancer Institute ORCID

Also Known As

C. Varamo, Chiara Varamo, Varamo, Chiara

Publications

402

Citations

H-Index

Concepts

All Affiliations

Candiolo Cancer Institute Fondazione Edo ed Elvo Tempia Sapienza University of Rome University of Turin Azienda Sanitaria Ospedaliera S.Croce e Carle Cuneo

About

Chiara Varamo is an author at Candiolo Cancer Institute specializing in cancer therapeutics, medicine, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	2	2	63
2	Pathology	2	2	63
3	Cell Biology	1	1	14
4	Pharmacology	1	1	14
5	Cancer Cell Biology	1	1	14

Chiara Varamo

Publications

253

Citations

H-Index

Page 1

	Year	Citations
Nucleotide metabolism in cancer cells fuels a UDP-driven macrophage cross-talk, promoting immunosuppression and immunotherapy resistance Tommaso Scolaro, Marta Manco, Mathieu Pecqueux, Nature Cancer	2024	51
Elevated basal antibody-dependent cell-mediated cytotoxicity (ADCC) and high epidermal growth factor receptor (EGFR) expression predict favourable outcome in patients with locally advanced head and neck cancer treated with cetuximab and radiotherapy Laura Lattanzio, Nerina Denaro, Daniela Vivenza, Cancer Immunology Immunotherapy Neck CancerRadiation TherapyMedicinePathologyHead And Neck Cancer	2017	49
Immunotherapy Bridge 2016 and Melanoma Bridge 2016: meeting abstracts Vera Hirsh, Sandro Pignata, Melissa Bersanelli, Journal of Translational Medicine	2017	43
Establishment and characterization of a human intrahepatic cholangiocarcinoma cell line derived from an Italian patient Giuliana Cavalloni, Caterina Peraldo‐Neia, Chiara Varamo, Tumor Biology	2015	40
Immunotherapy Bridge 2017 and Melanoma Bridge 2017: meeting abstracts David Carbone, Michael F. Sharpnack, Kai He, Journal of Translational Medicine	2018	28
Establishment and Characterization of a New Intrahepatic Cholangiocarcinoma Cell Line Resistant to Gemcitabine Chiara Varamo, Caterina Peraldo‐Neia, Paola Ostano, Cancers	2019	28
Preclinical activity of EGFR and MEK1/2 inhibitors in the treatment of biliary tract carcinoma Giuliana Cavalloni, Caterina Peraldo‐Neia, Chiara Varamo, Oncotarget PathologyCancer BiologyTumor BiologyCancer Cell BiologyAnti-cancer Agent	2016	14

Page 1